Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
Thyroidectomy, Radioactive Iodine Could Prevent More CV Events than Antithyroid Drugs
March 6th 2024A study suggests that opting for thyroid surgery or radioactive iodine therapy could be better for reducing long-term cardiovascular risk in hyperthyroidism patients compared to medication alone.
Read More
Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial
March 5th 2024Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.
Read More
Elevated Lp(a) Levels Linked to Cardiovascular Event Risk, Regardless of ASCVD History
March 4th 2024The latest analysis of the Mass General Brigham Lp(a) Registry highlights Lp(a)'s independent association with cardiovascular events, with these associations apparent in patients regardless of baseline cardiovascular history.
Read More
Cardiology Month in Review: February 2024
March 4th 2024Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.
Read More
VK2735, a Dual GLP-1/GIP RA, Showcases Weight Loss Effects in Phase 2 Trial
February 28th 2024Viking Therapeutics' dual GLP-1/GIP receptor agonist VK2735 showed promising weight reduction in the phase 2 VENTURE trial, with the 15 mg dose contributing to a 14% reduction in body weight from baseline to week 13.
Read More
OUtMATCH: Omalizumab Proves Utility in Multiple Food Allergies for Pediatric, Adult Patients
February 25th 2024Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.
Read More
Rilzabrutinib Reduces Itch, Hives in Chronic Spontaneous Urticaria in Phase 2 Trial
February 24th 2024Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.
Read More
Robert Wood, MD: Impact of Omalizumab Approval on Management of Pediatric Food Allergy
February 22nd 2024Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.
Read More
Experts' Perspectives: Top Issue Facing Cardiology in 2024
February 21st 2024This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.
Read More
Ahmad Masri, MD, MS: 2024 Update on Development and Future of Cardiac Myosin Inhibitor Class
February 19th 2024Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.
Read More
New Risk Score Outperforms Current Model, Could Improve Heart Transplant Allocation
February 13th 2024A novel risk score developed by University of Chicago investigators outperformed conventional models in predicting death in heart transplant candidates, which could help bring the field closer to optimal and equitable allocation.
Read More
Cardiology Month in Review: January 2024
February 6th 2024This recap of top cardiology news from January 2024 spotlights pipeline updates, new guidance on peripheral interventions, and a celebration of what may be the single most impactful public health address in the history of the United States.
Read More